APX 005M

Drug Profile

APX 005M

Alternative Names: APX 005; APX 005M; EPI-0050

Latest Information Update: 08 May 2017

Price : $50

At a glance

  • Originator Epitomics
  • Developer Apexigen; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; CD40 antigen stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Malignant melanoma
  • Phase I Solid tumours

Most Recent Events

  • 24 Apr 2017 Apexigen and Bristol-Myers Squibb plan a phase I/II trial for Non-small cell lung cancer and Melanoma (Metastatic disease, Inoperable/unresectable, Combination therapy, Second-line therapy or greater, Late-stage disease) in USA (NCT03123783)
  • 11 Apr 2017 Apexigen and Bristol-Myers Squibb enter into clinical trial collaboration for APX 005M in combination with nivolumab for Solid tumours
  • 21 Mar 2017 Phase-I/II clinical trials in Malignant melanoma (Metastatic disease, Late-stage disease, Combination therapy) in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top